慢性乙型肝炎患者抗病毒治疗与免疫细胞上PD-1/PD-L1表达的关系  

Relationship between antiviral therapy and PD-1/PD-L1 expression on immune cells in chronic hepatitis B patients

作　　者：程雪[1] 罗亚文[1] 易学东[2] 

机构地区：[1]遵义医学院附属医院感染科,贵州省遵义市563003 [2]遵义医学院附属医院药剂科,贵州省遵义市563003

出　　处：《世界华人消化杂志》2015年第12期1910-1916,共7页World Chinese Journal of Digestology

基　　金：贵州省科技厅社会发展攻关基金资助项目;No.黔科合SY字[2011]3048~~

摘　　要：在我国,乙型肝炎病毒(hepatitis B virus,HBV)在体内不断复制并由此导致的肝细胞免疫病理损伤是H B V感染后慢性化及病情加重的原因,因此,抗病毒是阻止病情进展的有效手段.在多种与宿主免疫调控异常有关的发病机制中,程序性死亡分子1(programmed death 1,PD-1)/程序性死亡分子1配体1(PD-1 ligand 1,PD-L1)通路被认为与HBV感染后结局相关,本文就慢性乙型肝炎(chronic hepatitis B,CHB)患者抗病毒治疗与免疫细胞上PD-1/PD-L1表达间关系进行综述.In China, the immune pathological damage of hepatocytes induced by the persistent replication of hepatitis B virus （HBV） is regarded as the reason that leads to HBV infection chronicity and aggravates the patient＇s condition. Therefore, antiviral therapy is effective measures to prevent the aggravation of patient＇s condition after HBV infection. Among several pathogenic mechanisms associated with the host immune dysregulation, programmed death I （PD-1）/PD-1 ligand I （PD-L1） pathway is believed to be related with the outcome of HBV infection. This review will discuss the relationship between antiviral therapy and PD-1/PD-L1 expression on immune cells in chronic hepatitis B （CHB） patients.

关 键 词：慢性乙型肝炎 抗病毒治疗 程序性死亡分子1/程序性死亡分子1配体 

分 类 号：R512.62[医药卫生—内科学]